UBS analyst Kevin Caliendo raised the firm’s price target on Alignment Healthcare (ALHC) to $18 from $17 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare Surpasses Q3 2025 Financial Expectations
- Alignment Healthcare: Strong Financial Performance and Strategic Growth Positioning Earns Buy Rating
- Alignment Healthcare reports Q3 EPS 2c, consensus (1c)
- Alignment Health Plan, Suvida Healthcare partner for bilingual care
- Alignment Healthcare initiated with a Buy at Goldman Sachs